Ikarian Capital’s Tempest Therapeutics TPST Stock Holding History

Ikarian Capital’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,099	Closed	-$87.9K	–	217
2024 Q4	$87.9K	Sell	8,099 -24	-0.3%	-$310	0.01%	156
2024 Q3	$148K	Hold	8,123	–	–	0.02%	139
2024 Q2	$231K	Hold	8,123	–	–	0.04%	105
2024 Q1	$413K	Hold	8,123	–	–	0.05%	123
2023 Q4	$465K	Buy	+8,123	New	+$385K	0.04%	117
2022 Q3	–	Sell	-4,756	Closed	-$132K	–	157
2022 Q2	$132K	Hold	4,756	–	–	0.02%	127
2022 Q1	$210K	Buy	4,756 +233	+5%	+$10.6K	0.03%	163
2021 Q4	$310K	Hold	4,523	–	–	0.05%	148
2021 Q3	$851K	Sell	4,523 -2,390	-35%	-$465K	0.06%	160
2021 Q2	$1M	Hold	6,913	–	–	0.08%	161
2021 Q1	$1.62M	Buy	6,913 +6,220	+898%	+$2.51M	0.05%	214
2020 Q4	$289K	Hold	693	–	–	0.01%	207
2020 Q3	$220K	Hold	693	–	–	0.02%	153
2020 Q2	$238K	Buy	+693	New	+$276K	0.02%	145

Other funds holding TPST

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ikarian Capital's TPST Position: Q1 2025 in Review

Ikarian Capital sold out of Tempest Therapeutics (TPST) in Q1 2025, closing a stake of 8,099 shares — an estimated $87.9K sold.

Ikarian Capital first reported a position in TPST in Q2 2020 and held it in 14 quarters. The position peaked at $1.62M in Q1 2021. 23 funds tracked by Wall St. Rank hold TPST as of Q1 2025.

Ikarian Capital reported no remaining Tempest Therapeutics position as of Q1 2025 after selling out during the quarter.
Ikarian Capital sold 8,099 Tempest Therapeutics shares in Q1 2025, an estimated $87.9K.
Ikarian Capital first reported a position in Tempest Therapeutics in Q2 2020 and held it in 14 quarters.
Ikarian Capital's Tempest Therapeutics position peaked at $1.62M in Q1 2021.
23 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2025.

Based on Ikarian Capital's 13F filing for Q1 2025, filed 15 May 2025.